Citadel Advisors
KRYS icon

Citadel Advisors’s Krystal Biotech KRYS Stock Holding History

Citadel Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.88M Buy
18,900
+200
+1% +$53.2K ﹤0.01% 4374
2025
Q4 		$4.61M Buy
18,700
+4,600
+33% +$968K ﹤0.01% 4412
2025
Q3 		$2.49M Sell
14,100
-7,400
-34% -$1.11M ﹤0.01% 5633
2025
Q2 		$2.96M Buy
21,500
+11,900
+124% +$1.75M ﹤0.01% 5002
2025
Q1 		$1.73M Sell
9,600
-14,500
-60% -$2.44M ﹤0.01% 5809
2024
Q4 		$3.78M Sell
24,100
-22,200
-48% -$3.94M ﹤0.01% 4437
2024
Q3 		$8.43M Buy
46,300
+18,900
+69% +$3.64M ﹤0.01% 3172
2024
Q2 		$5.03M Sell
27,400
-12,900
-32% -$2.17M ﹤0.01% 3745
2024
Q1 		$7.17M Buy
40,300
+700
+2% +$97.2K ﹤0.01% 3404
2023
Q4 		$4.91M Buy
39,600
+23,500
+146% +$2.61M ﹤0.01% 3820
2023
Q3 		$1.87M Buy
16,100
+6,200
+63% +$756K ﹤0.01% 5339
2023
Q2 		$1.16M Sell
9,900
-1,300
-12% -$133K ﹤0.01% 6150
2023
Q1 		$897K Sell
11,200
-6,300
-36% -$495K ﹤0.01% 7018
2022
Q4 		$1.39M Buy
17,500
+5,800
+50% +$430K ﹤0.01% 6190
2022
Q3 		$815K Sell
11,700
-7,800
-40% -$564K ﹤0.01% 7434
2022
Q2 		$1.28M Buy
19,500
+8,600
+79% +$535K ﹤0.01% 6457
2022
Q1 		$725K Sell
10,900
-32,000
-75% -$2M ﹤0.01% 8484
2021
Q4 		$3M Sell
42,900
-15,300
-26% -$891K ﹤0.01% 5336
2021
Q3 		$3.04M Buy
58,200
+49,700
+585% +$2.94M ﹤0.01% 5335
2021
Q2 		$578K Buy
8,500
+4,300
+102% +$300K ﹤0.01% 9726
2021
Q1 		$324K Sell
4,200
-4,600
-52% -$334K ﹤0.01% 10670
2020
Q4 		$528K Buy
+8,800
New +$439K ﹤0.01% 8050

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's KRYS Position: Q1 2026 in Review

Citadel Advisors reduced its Krystal Biotech (KRYS) stake by 99% in Q1 2026, selling an estimated $102M and leaving 2,726 shares worth $704K. The position accounts for ﹤0.01% of the portfolio, ranked #8483.

Citadel Advisors first reported a position in KRYS in Q4 2018 and has held it in 26 quarters since. The position peaked at $112M in Q3 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Citadel Advisors held 2,726 shares of Krystal Biotech worth $704K as of Q1 2026.
  • Citadel Advisors sold 383,779 Krystal Biotech shares in Q1 2026, an estimated $102M.
  • Krystal Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8483 holding.
  • Citadel Advisors first reported a position in Krystal Biotech in Q4 2018 and has held it in 26 quarters since.
  • Citadel Advisors's Krystal Biotech position peaked at $112M in Q3 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.